RE: RNS21 Aug 2020 11:17
Review of Majority Shareholders
Aibek Oraziman 354,210,643 18.8
Aidana Oraziman 354,210,642 18.8
Rafik Oraziman 57,369,124 3.1
Kuat Oraziman 41,485,330 2.2
Oraziman family total 807,275,739 44.25 (Current market value £21,392,807.08 @ 2.65pps)
Dae Han New Pharm Limited 224,830,964 13.5
Kairat Satylganov 221,625,001 11.8
Raushan Sagdievya 66,425,290 3.5
Total No. of Shares in issue 1,882,660,885
There's been some discussion about agendas by Orazimans and the game they're playing.
To be brutally honest, if you're playing a game in AIM you wouldn't keep taking shares. If they take this private they lose out just like the rest of us. It's the only fact that's keeping me sane.
Kuat wouldn't have shared his majority stake amongst his family if he was expecting it to amount to nothing.
At the end of the day, they have the most to lose.
Despite my scepticism and frustration growing from lack of good news, today I'm on the opposite side of the seesaw and optimistic that good news is on the horizon. They just need to crack one of the deeps, say goodbye to the single digits and and onward and upwards towards the pound party.